CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now?
- 1 November 2015
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (21), 4743-4746
- https://doi.org/10.1158/1078-0432.ccr-14-3127
Abstract
Desmedt and colleagues published two articles, one in the June 1, 2007 issue, and the other in the August 15, 2008, issue of Clinical Cancer Research, that showed gene-expression signatures to be proliferation driven and time dependent, with their prognostic power decreasing with increasing follow-up years. Moreover, the articles showed that immune response is a crucial determinant of prognosis in the HER2-positive and estrogen receptor–negative/HER2-negative subtypes, providing a rationale to further explore the role of the antitumor immune response in these breast cancer subtypes. Clin Cancer Res; 21(21); 4743–6. ©2015 AACR. See related articles by Desmedt et al., Clin Cancer Res 2007;13(11) June 1, 2007;3207–14 and Desmedt et al., Clin Cancer Res 2008;14(16) August 15, 2008;5158–65.Keywords
Other Versions
This publication has 33 references indexed in Scilit:
- CD4+ follicular helper T cell infiltration predicts breast cancer survivalJCI Insight, 2013
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled AnalysisJournal of Clinical Oncology, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJCI Insight, 2011
- Comparison of prognostic gene expression signatures for breast cancerBMC Genomics, 2008
- Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular SubtypesClinical Cancer Research, 2008
- Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?Nature Reviews Cancer, 2007
- Concordance among Gene-Expression–Based Predictors for Breast CancerThe New England Journal of Medicine, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002